Search

Displaying results 4621 - 4630 of 6949 in total
  1. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis.

  2. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

    Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitors
  3. Drug

    Metralindole

    go.drugbank.com/drugs/DB09306
    Experimental

    In Russia, this drug was investigated for potential antidepressant activity.

  4. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  5. Drug

    COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB15845
    Experimental

    As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’

  6. Drug

    Amniotic Epithelial Cells

    go.drugbank.com/drugs/DB15868
    Investigational

    [A220183,T823] These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.[A220183]

  7. Target

    Integrin alpha-X

    go.drugbank.com/bio_entities/BE0009967
    TargetHumans

    Functions as a receptor of the erythrocyte-specific adhesion molecule ICAM4 and mediates erythrophagocytosis (PubMed:16985175) … Integrin alpha-X/beta-2 is a receptor for fibrinogen. It recognizes the sequence G-P-R in fibrinogen. It mediates cell-cell interaction during inflammatory responses.

    Synonyms: Leukocyte adhesion receptor p150,95
  8. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series

  9. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight.

  10. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.